Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept & continue
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Sunak orders plan for windfall tax on electricity generators
    • Chinese and Russian nuclear bombers fly over Sea of Japan as Biden visits Tokyo
    • Joe Biden pledges to defend Taiwan militarily if China invades
    • Erdoğan says he no longer recognises existence of Greece’s leader
    • Partygate photos prompt renewed criticism of Boris Johnson
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Chinese and Russian nuclear bombers fly over Sea of Japan as Biden visits Tokyo
    • Joe Biden pledges to defend Taiwan militarily if China invades
    • Lies weaken Russia in its trial of strength with the west
    • SEC fines BNY Mellon over ESG in first case of its kind
    • Snap spooks investors with macroeconomic warning
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • $40bn crypto collapse turns South Korea against the ‘Lunatic’ leader
    • HSBC suspends banker over climate change comments
    • SEC fines BNY Mellon over ESG in first case of its kind
    • Clifford Chance raises pay for newly qualified lawyers to £125,000 a year
    • UK professional services firms seek exemptions to ban on Russia work
  • Tech
  • Markets
    Sections
    • Markets Home
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    • Cryptocurrencies
    Most Read
    • Live news: Glencore to face court over bribery and corruption claims
    • SEC prepares to crack down on misleading ESG investment claims
    • Live news updates from May 23: US to defend Taiwan if China invades, Zelensky floats reconstruction plan using frozen Russian assets
    • Banks and funds stash record $2tn overnight at Fed facility
    • Crypto links with banks pose threat to financial stability, says ECB
  • Climate
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
    Most Read
    • Lies weaken Russia in its trial of strength with the west
    • How the great generational wealth transfer will shape our political future
    • Trump is losing his stranglehold on Republicans
    • I tried remote working from this subtropical island. Don’t get too jealous
    • The Irish language is having a moment in the sun
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    Most Read
    • ‘A bonfire of the decencies’: Peter Hennessy on Boris Johnson’s government
    • The cold call is back and worse than ever
    • Vive la différence between work and play
    • Why presenteeism is an enduring corporate narcotic
    • As a longtime trailing spouse, how do I get back into full-time work?
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
    Most Read
    • I tried remote working from this subtropical island. Don’t get too jealous
    • The Norfolk Lourdes: England’s lost Holy Land
    • Russia: Revolution and Civil War by Antony Beevor — monsters of the past
    • Bodes well – the New York couple marrying menswear and design
    • Five of Singapore’s best places for brunch with a difference
  • How to Spend It
MenuSearch
  • Home
  • World
  • US
  • Companies
  • Tech
  • Markets
  • Climate
  • Opinion
  • Work & Careers
  • Life & Arts
  • How to Spend It
Financial Times
SubscribeSign In

Your guide to a disrupted world

Start a 4-week trial

Pfizer Inc

Add to myFT Digest

Add this topic to your myFT Digest for news straight to your inbox

  • Monday, 23 May, 2022
    Covid-19 vaccines
    Pfizer to seek US emergency approval of Covid vaccine for under 5s

    Jabs for youngest children offer potential new market amid global glut of adult doses

  • Tuesday, 10 May, 2022
    Lex
    Pfizer: drugmaker puts Covid cash to work Premium content

    Pharma group’s chief is right to take advantage of the market sell-off to boost pipeline

  • Tuesday, 10 May, 2022
    Pfizer to buy biotech group Biohaven for $11.6bn

    US pharmaceutical group’s biggest deal in more than 5 years comes as sales of its Covid vaccine are set to fall

  • Tuesday, 19 April, 2022
    Covid-19 vaccines
    Moderna and Pfizer urged to share vaccine technology with developing world

    Proxy advisers back shareholder resolutions as new shot shows promising results

  • Tuesday, 5 April, 2022
    Chief executives of mRNA vaccine groups earned $100mn in pandemic pay

    Remuneration at the three big jab makers reflects surge in value of share options

  • Wednesday, 16 February, 2022
    Covid-19 vaccines
    Children aged 5 to 11 to be offered Covid vaccine in England

    Johnson government announces plan after similar moves in Scotland and Wales

  • Friday, 11 February, 2022
    Pfizer’s Covid vaccine for kids delayed after FDA postpones meeting

    US drugs regulator says it needs more time to evaluate low-dose jab for children under 5

  • Tuesday, 8 February, 2022
    Pfizer’s 2022 outlook falls short of Wall Street’s lofty expectations

    Company projects $54bn in sales from Covid vaccine and treatment but some experts predict pandemic has peaked

  • Tuesday, 25 January, 2022
    Covid-19 vaccines
    BioNTech/Pfizer start clinical trial of Omicron vaccine

    First human study of variant-specific jab by big western drugmaker could prompt shift in manufacturing

  • Tuesday, 18 January, 2022
    Covid-19 vaccines
    Fourth Pfizer jab ineffective in blocking Omicron, Israeli study shows

    Early findings suggest level of antibodies needed to protect against variant ‘too high’ for jab to induce

  • Sunday, 16 January, 2022
    Mergers & Acquisitions
    GSK and Pfizer hold out for £60bn bid for consumer health unit

    Investors push for higher price or spin-off after rejecting Unilever’s £50bn offer

  • Saturday, 15 January, 2022
    Unilever PLC
    GSK rejects Unilever’s £50bn offer for consumer unit

    The division jointly owned by Pfizer is due to be spun off in London listing later this year

  • Thursday, 6 January, 2022
    Covid-19 vaccines
    Covid vaccine makers face investor pressure over global access

    Asset managers call for pharma executive pay to be linked to equitable distribution of jabs

  • Wednesday, 5 January, 2022
    Pfizer and BioNTech team up to develop mRNA-based shingles vaccine

    Drugmakers set to take on GSK as they aim to replicate Covid jab success

  • Thursday, 23 December, 2021
    News in-depthMedical science
    Covid vaccine winners set sights on flu as their next big target

    New mRNA technology could make jabs better-matched to different annual strains and improve efficacy

  • Wednesday, 22 December, 2021
    Coronavirus treatment
    White House warns Pfizer Covid-19 pill will not be widely available for months

    Complex nature of drug means it will take more than half a year to make the 10m courses that are on order

  • Tuesday, 14 December, 2021
    Coronavirus treatment
    Pfizer says Covid drug offers strong protection and should work against Omicron

    Data confirm Paxlovid cuts risk of hospitalisation or death by 89% for highly vulnerable patients

  • Tuesday, 14 December, 2021
    Covid-19 vaccines
    Two Pfizer doses give 70% protection against hospitalisation from Omicron, study shows

    Report suggests share of cases that develop into severe disease should be lower than in previous waves

  • Friday, 10 December, 2021
    Special ReportNorth America Innovative Lawyers
    FT North American Innovative Lawyers Awards 2021 — winners announced

    Awards highlights include: law-firm people strategies; life after Libor; and the most innovative law firms and individuals

  • Friday, 10 December, 2021
    Special ReportNorth America Innovative Lawyers
    In-house legal teams develop new attitude to risk

    Urgency on issues such as vaccine development and climate change has brought permanent change. Plus: FT most innovative in-house legal teams

  • Wednesday, 8 December, 2021
    Covid-19 vaccines
    Pfizer says three vaccine doses offer protection against Omicron

    Preliminary research suggests two shots show significantly reduced effectiveness against new coronavirus variant

  • Sunday, 5 December, 2021
    Coronavirus treatment
    Merck takes aim at Pfizer’s Covid pill as concerns linger over its own drug

    Executive says patients on other medications will not be able to take competing antiviral treatment

  • Friday, 3 December, 2021
    Moral Money
    Sustainable investors target Pfizer’s pandemic profits Premium content

    Plus, corporate political donations rise up the governance agenda and regulators eye sustainability-linked derivatives

  • Thursday, 2 December, 2021
    Covid-19 vaccines
    UK’s ‘mix and match’ booster jab strategy backed by new study

    Research shows mRNA vaccines from Pfizer and Moderna are by far most effective third doses

  • Wednesday, 1 December, 2021
    ExplainerCovid-19 vaccines
    Will Covid vaccines have to be updated for Omicron?

    Drugmakers are stress-testing existing jabs while preparing new formulas

Previous page You are on page 1 Next page

Topics related to Health & pharmaceuticals

Useful links

Support

View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

Legal & Privacy

Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

Services

Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT TransactSecondary Schools

Tools

PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

Community & Events

FT CommunityFT LiveFT ForumsFT Board DirectorBoard Director Programme

More from the FT Group

Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2022. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Financial Times

International Edition

Subscribe for full access
  • Switch to UK Edition
  • Top sections
  • Home
  • World
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
  • US
    • US Economy
    • US Companies
    • US Politics & Policy
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
  • Markets
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    • Cryptocurrencies
  • Climate
  • Opinion
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
    • Next Act
  • How to Spend It
  • Special Reports
  • FT recommends
  • Lex
  • Alphaville
  • Lunch with the FT
  • FT Globetrotter
  • #techAsia
  • Moral Money
  • FTfm
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • FT Community
    • FT Live
    • FT Forums
    • Board Director Programme
  • myFT
  • Portfolio
  • Today's Newspaper (ePaper)
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In